What is the role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction?

Citations Over TimeTop 10% of 2007 papers

Abstract

Oestrogen therapy is the gold standard treatment for hot flushes/night sweats, but it and oestrogen/progestin are not suitable for all women. MPA (medroxyprogesterone acetate) reduces hot flushes, but its effectiveness compared with oestrogen is unknown. In the present study, oral oestrogen [CEE (conjugated equine oestrogen)] and MPA were compared for their effects on hot flushes in a planned analysis of a secondary outcome for a 1-year randomized double-blind parallel group controlled trial in an urban academic medical centre. Participants were healthy menstruating women prior to hysterectomy/ovariectomy for benign disease. A total of 41 women {age, 45 (5) years [value is mean (S.D.)]} were enrolled; 38 women were included in this analysis of daily identical capsules containing CEE (0.6 mg/day) or MPA (10 mg/day). Demographic variables did not differ at baseline. Daily data provided the number of night and day flushes compared by group. The vasomotor symptom day-to-day intensity change was assessed by therapy assignment. Hot flushes/night sweats were well controlled in both groups, one occurred on average every third day and every fourth night. Mean/day daytime occurrences were 0.363 and 0.187 with CEE and MPA respectively, but were not significantly different (P=0.156). Night sweats also did not differ significantly (P=0.766). Therapies were statistically equivalent (within one event/24 h) in the control of vasomotor symptoms. Day-to-day hot flush intensity decreased with MPA and tended to remain stable with CEE (P<0.001). In conclusion, this analysis demonstrates that MPA and CEE are equivalent and effective in the control of the number of hot flushes/night sweats immediately following premenopausal ovariectomy.

Related Papers

• → Relationship of Noninvasive Assessment of Arterial Stiffness with 10-Year Atherosclerotic Cardiovascular Disease (ASCVD) Risk in a General Middle-Age and Elderly Population(2021)10 cited
• → VALIDATION OF THE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) POOLED COHORT RISK EQUATIONS BY EDUCATION LEVEL: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY(2016)5 cited
• CLINICAL STUDIES Coronary Atherosclerosis Anemia as a Risk Factor for Cardiovascular Disease in the Atherosclerosis Risk in Communities (ARIC) Study(2002)
• → THE ASSOCIATION OF GROWTH DIFFERENTIATION FACTOR-15 AND RISK OF SHORT-TERM INCIDENT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, HEART FAILURE HOSPITALIZATION, AND ALL-CAUSE MORTALITY IN OLDER ADULTS: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY(2020)
• → Gambling With Cardiovascular Disease Risk Models: How to Choose and How to Use(2021)